Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0017168 (gastroesophageal reflux disease)
 11,783 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Was conducted a muIticenter study VIA APIA, in which the impact of gaviscon forte (suspension) on symptoms, general state and quality of life of 148 patients (male 53, female 95, age 42.9 +/- 15.6) with gastroesophageal reflux disease (GERD) were investigated. The patients had undergone clinical evaluation of dynamics of GERD symptoms (Likert scale), general state (Visual Analogue Scale, questionnaire SAN) and quality of life (SF-36). It was shown that 14-days treatment with gaviscon forte provided symptoms relief in 84.5% patients and conducted improvement of general state and quality of life. Gaviscon forte recommended as drug of choice in initial treatment for the first time visited patient with heartburn before endoscopy and for pathogenetic treatment of typical reflux syndrome.
 ...
PMID:[Restoration of the quality of life by eliminating and prevention of heartburn by alginate: results of multicenter study "VIA APIA"]. 2073 Nov 69

Was made a comparative evaluation of the influence of treatment of gastroesophageal reflux disease (GERD) on the course of inflammatory periodontal diseases in patients with combined pathology of periodontal and GERD. Was performed an assessment of GERD symptom severity, the establishment of periodontal status of patients and analysis of the effects of GERD therapy on the course parodontopaty inflammatory genesis (chronic catarrhal gingivitis and chronic periodontitis mild). In patients with inflammatory periodontal diseases, coupled with GERD, was marked by a more pronounced therapeutic effect of combined treatment in comparison with isolated local treatment CDW (HKG and HGPI), which was reflected in the improvement of the parameters of the microcirculation system of periodontal tissues. This suggests the presence of pathogenic link between chronic inflammatory periodontal diseases (CDW) and the presence of pathological gastroesophageal reflux.
 ...
PMID:[Dynamics of inflammatory periodontal diseases under the influence of gastroesophageal reflux disease therapy]. 2126 26

Was made an investigation of the effectiveness of pantoprazole (sanpraz, "SanFarma", India) at gastroesophageal reflux disease (GERD). 53 patients with GERD, including 20--with reflux esophagitis, received a daily dose of pantoprazole 40 mg to 28 days. To the 7 day of treatment heartburn was broke in 63.3%, regurgitation--in 65% of patients initially experiencing these symptoms. The 14-th day of treatment heartburn was broke in 83.7%, regurgitation--in 90%. Endoscopic remission in 28-th day of treatment was obtained in 85% of patients with reflux esophagitis. Broking of symptoms was accompanied by significant improvement in well-being and quality of life of patients. Treatment of a standard dose of pantoprazole was ineffective in 16.3% of patients. The reasons for the conservation of heartburn in 4.1% of the cases was an individual characteristics of the pharmacokinetics drug, in 12.2%--non-reflux mechanisms of symptoms in the face of mental status.
 ...
PMID:[Pharmacokinetics of the proton pump inhibitors and psychological status in patients as factors that influence the efficiency of treatment of GERD with pantoprazole]. 2142 32

Chronic esophagitis in children etiologically are heterogeneous. Was observed 83 patients aged from 3 to 17 years with histologically defined chronic esophagitis, 58 of them suffered from food and respiratory allergies. All children underwented endoscopy, morphological and immunohistochemical study of the esophagus biopsies with the definition IgE, IgA herpes simplex virus (HSV), cytomegalovirus (CMV) and Epstein - Barr virus (EBV) in the mucous membrane. The presence of chronic infection was established in 77 out of 83 (92.8%) children. All the patients underwented daily pH meters. GERD was diagnosed in 33 children. GERD was characterized by typical symptoms, combined with gastroduodenal pathology, usually Hp-associated, and increased gastric secretion. Morphologically at 15% of the patients with gastric metaplasia was found moderate inflammation. During examination of patients with allergic esophagitis was neither clinical nor explicit endoscopic manifestations, eosinophilic infiltration was observed in some patients, but inflammatory activity was lower than at GERD and infections. Esophagitis in chronic viral infections was characterized by a higher frequency of erosive changes, higher activity of inflammation. The combination of the three etiological factors were associated with more severe lesions of the esophagus.
 ...
PMID:[Heterogeneity of chronic esophagitis in childhood]. 2156 Mar 83

There are demonstrated results of a prospective comparative study on clinical efficacy and tolerability of Panum (INN: pantoprazole) under the sponsorship of"Unique Pharmaceutical Laboratories (India)". Were evaluated the results of a 28-day course of treatment of 30 patients with GERD, including those with severe reflux esophagitis (erosive and ulcerative), who received 40 mg of pantoprazole as monotherapy. Was found an algorithm with an intermediate control efficacy to individualizing the approach to therapy. As a result 16,7% of patients with severe reflux esophagitis required increasing the dose of pantoprazole to 80 mg/day in two divided doses, and the rest (83,3%) patients to achieve clinical and endoscopic remission of GERD was sufficient single dose of 40 mg of the drug. The results of this study indicated the efficacy and safety of the Panum drug in the treatment of GERD, including its complicated forms.
 ...
PMID:[Panum (pantoprazole) effectiveness in the treatment of patients with GERD]. 2191 7